SYRE vs. LPTH
SYRE (Spyre Therapeutics Inc.) and LPTH (LightPath Technologies, Inc.) are both stocks. SYRE operates in Biotechnology (Healthcare), while LPTH operates in Electronic Components (Technology). Over the past 10 years, SYRE returned -2.85%/yr vs 24.10%/yr for LPTH. At a 0.14 correlation, their price movements are largely independent.
Performance
SYRE vs. LPTH - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SYRE achieves a 206.23% return, which is significantly higher than LPTH's 37.13% return. Over the past 10 years, SYRE has underperformed LPTH with an annualized return of -2.85%, while LPTH has yielded a comparatively higher 24.10% annualized return.
SYRE
- 1D
- 13.56%
- 1M
- 35.48%
- YTD
- 206.23%
- 6M
- 193.33%
- 1Y
- 568.35%
- 3Y*
- 115.67%
- 5Y*
- -9.28%
- 10Y*
- -2.85%
LPTH
- 1D
- -2.24%
- 1M
- -12.63%
- YTD
- 37.13%
- 6M
- 73.62%
- 1Y
- 380.84%
- 3Y*
- 123.87%
- 5Y*
- 40.97%
- 10Y*
- 24.10%
SYRE vs. LPTH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SYRE Spyre Therapeutics Inc. | 206.23% | 40.72% | 8.18% | 91.33% | -90.53% | -39.64% | 3.01% | 2.00% | 38.45% | 24.37% |
LPTH LightPath Technologies, Inc. | 37.13% | 205.95% | 180.16% | 3.28% | -50.00% | -37.76% | 440.69% | -51.34% | -32.88% | 44.16% |
Correlation
The correlation between SYRE and LPTH is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.12 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Apr 7, 2016 | 0.14 |
Fundamentals
SYRE:
$34.72B
LPTH:
$868.30M
SYRE:
-$0.88
LPTH:
-$85.64K
SYRE:
225.37
LPTH:
0.00
SYRE:
66.20
LPTH:
0.00
SYRE:
$90.49M
LPTH:
$19.15T
SYRE:
$0.00
LPTH:
$6.96T
SYRE:
-$171.29M
LPTH:
-$4.25T
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SYRE vs. LPTH — Risk / Return Rank
SYRE
LPTH
SYRE vs. LPTH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Spyre Therapeutics Inc. (SYRE) and LightPath Technologies, Inc. (LPTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SYRE | LPTH | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +5.02 | ||
| Sortino ratioReturn per unit of downside risk | +3.05 | ||
| Omega ratioGain probability vs. loss probability | 1.74 | 1.39 | +0.35 |
| Calmar ratioReturn relative to maximum drawdown | 34.16 | 9.47 | +24.68 |
| Martin ratioReturn relative to average drawdown | 95.79 | 21.64 | +74.15 |
Loading charts...
Drawdowns
SYRE vs. LPTH - Drawdown Comparison
The maximum SYRE drawdown since its inception was -99.11%, roughly equal to the maximum LPTH drawdown of -99.65%. Use the drawdown chart below to compare losses from any high point for SYRE and LPTH.
Loading charts...
Drawdown Indicators
| SYRE | LPTH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.11% | -99.65% | +0.54% |
Max Drawdown (1Y)Largest decline over 1 year | -16.79% | -40.52% | +23.73% |
Max Drawdown (3Y)Largest decline over 3 years | -73.99% | -61.08% | -12.91% |
Max Drawdown (5Y)Largest decline over 5 years | -98.74% | -64.66% | -34.08% |
Max Drawdown (10Y)Largest decline over 10 years | -99.04% | -86.28% | -12.76% |
Current DrawdownCurrent decline from peak | -66.53% | -77.32% | +10.79% |
Average DrawdownAverage peak-to-trough decline | -62.69% | -86.29% | +23.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.98% | 17.70% | -11.72% |
Volatility
SYRE vs. LPTH - Volatility Comparison
The current volatility for Spyre Therapeutics Inc. (SYRE) is 20.51%, while LightPath Technologies, Inc. (LPTH) has a volatility of 35.11%. This indicates that SYRE experiences smaller price fluctuations and is considered to be less risky than LPTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SYRE | LPTH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.51% | 35.11% | -14.60% |
Volatility (6M)Calculated over the trailing 6-month period | 47.36% | 82.56% | -35.20% |
Volatility (1Y)Calculated over the trailing 1-year period | 68.82% | 115.39% | -46.57% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 179.28% | 83.10% | +96.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 136.27% | 79.64% | +56.63% |
Dividends
SYRE vs. LPTH - Dividend Comparison
Neither SYRE nor LPTH has paid dividends to shareholders.
Financials
SYRE vs. LPTH - Financials Comparison
This section allows you to compare key financial metrics between Spyre Therapeutics Inc. and LightPath Technologies, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SYRE and LPTH have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LPTH has higher volatility (35.11%) compared to SYRE (20.51%). In terms of maximum drawdown, SYRE dropped -99.11% vs LPTH's -99.65%.
SYRE currently has the higher Sharpe Ratio (8.35 vs 3.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SYRE and LPTH
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer